Core Insights - IceCure Medical Ltd. has received a Notice of Allowance for its patent application titled 'Cryogen Flow Control', which is expected to enhance the efficiency of cryoablation technology and expand its indications [1][2] - The ProSense® Cryoablation System utilizes liquid nitrogen to destroy tumors through freezing, providing a minimally invasive treatment option for various types of tumors [3][5] - The company is awaiting FDA marketing approval for ProSense® in early-stage breast cancer, which is crucial for its market traction [2][5] Patent and Technology - The 'Cryogen Flow Control' patent, once granted, will be effective until 2045 and is already granted in Japan, with pending approvals in the EU and other major markets [1][2] - This technology aims to optimize cryogenic delivery by using sensor data to regulate cryogen flow, ensuring precise temperature control for effective treatment [2] Product Overview - ProSense® is designed to create large lethal zones for maximum efficacy in tumor destruction, applicable to benign and cancerous lesions in breast, kidney, lung, and liver [3][5] - The system enhances patient and provider value by accelerating recovery, reducing pain, and minimizing surgical risks, making it suitable for office-based procedures [4][5] Market Position - IceCure Medical positions itself as a global leader in liquid nitrogen-based cryoablation technology, focusing on innovation and commercial rollout of its systems [2][5]

Core Viewpoint - IceCure Medical Ltd. is awaiting FDA marketing authorization for its ProSense® system, aimed at treating early-stage low-risk breast cancer in women aged 70 and over, while experiencing growing interest in North America [1][2][3]. Company Developments - The proposed post-market study plan has been delivered to the FDA, with a decision expected after review by the Center for Devices and Radiological Health [2]. - ProSense® sales in North America have shown year-over-year growth, with an estimated 46,000 women in the U.S. annually seeking this minimally invasive treatment option [3]. - The company’s largest investor has provided a $2 million unsecured loan, indicating confidence in the technology and its market potential [3]. Financial Performance - Revenue for the three months ended March 31, 2025, was $725,000, a 2% decrease from $743,000 in the same period in 2024, primarily due to a decline in Asia, offset by increases in Europe and North America [6]. - Gross profit for the same period was $218,000, with a gross margin of 30%, down from 36% in the previous year [6]. - Research and development expenses decreased by 15% to $1,664,000, while sales and marketing expenses increased by 24% to $1,289,000 [7]. Cash Position - As of March 31, 2025, the company had cash and cash equivalents of approximately $6.04 million, which increased to approximately $6.2 million by May 27, 2025, including the recent $2 million loan [9]. Upcoming Milestones - Terumo Corporation is expected to file for regulatory approval of ProSense® in Japan in the second half of 2025 [5]. - Additional third-party data on ProSense® is anticipated to be published in medical journals and presented at conferences [5].

Core Viewpoint - IceCure Medical Ltd. is set to release its financial and operational results for Q1 2025 on May 28, 2025, before the Nasdaq opens, followed by a conference call to discuss these results and other corporate developments [1]. Group 1: Company Overview - IceCure Medical specializes in minimally-invasive cryoablation technology that targets tumor destruction through freezing, serving as an alternative to surgical tumor removal [2]. - The company focuses on treating various types of cancer, including breast, kidney, bone, and lung cancer, using its ProSense® system, which is marketed globally [2]. Group 2: Upcoming Events - A conference call will take place on May 28, 2025, at 10:00 a.m. EDT, where the company will discuss its financial results and other developments [1]. - The call can be accessed via a U.S. toll-free number and an international number, with a live webcast available online [2].

Core Insights - IceCure Medical Ltd. is focused on developing minimally-invasive cryoablation technology for tumor destruction, participating in the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium to promote its ProSense® system [1][4] Company Participation and Training - IceCure sponsored sold-out SBI Breast Cryoablation courses, indicating a growing interest among radiologists in integrating ProSense® into their practices [2] - The company hosted a VIP Exhibitor Hour featuring Dr. Robert Ward, who discussed the rationale and techniques behind breast cryoablation, contributing to the clinical data supporting the use of ProSense® [3] Product Overview - ProSense® is a cryoablation system that utilizes liquid nitrogen to create lethal zones for tumor destruction, applicable to various lesions including breast, kidney, lung, and liver [6][8] - The system enhances patient and provider value by accelerating recovery and reducing pain and surgical risks, making it suitable for office-based procedures [7] Industry Alignment - The mission of IceCure aligns with SBI's focus on early detection and treatment of breast cancer, aiming to minimize its impact [4][5]